FDA Drug Safety Communication: FDA Recommends Against Use of Revatio (Sildenafil) in Children with Pulmonary Hypertension

Why It Matters

The warning removes a common off‑label therapy for a high‑risk pediatric condition, forcing clinicians to seek safer alternatives and prompting tighter regulatory scrutiny of pediatric drug use.

Key Takeaways

• FDA advises against pediatric Revatio use.
• High-dose sildenafil increased child mortality 3.5‑fold.
• Low doses showed no exercise benefit.
• Off‑label pediatric prescribing now discouraged.
• Manufacturer must study adult death risk.

Pulse Analysis

The FDA’s latest drug safety communication marks a decisive shift in the management of pediatric pulmonary arterial hypertension (PAH). After a 16‑week, dose‑ranging trial involving 234 children followed by up to seven years of observation, the agency concluded that Revatio (sildenafil) offers no measurable improvement in exercise capacity and, at higher doses, triples the risk of death. The hazard ratio of 3.5 for high‑dose versus low‑dose patients, coupled with a lack of efficacy, prompted the FDA to add a contraindication for anyone aged 1‑17 to the drug’s label.

This ruling eliminates a widely used off‑label option for clinicians treating a vulnerable population with limited therapeutic choices. Pediatric cardiologists must now rely on alternative pathways, such as endothelin‑receptor antagonists or prostacyclin analogues, while awaiting data from newer agents. The decision also underscores the importance of age‑specific dosing studies; adult dosing regimens cannot be extrapolated safely to children. Families are advised not to alter or discontinue therapy without professional guidance, and adverse events should be reported through FDA MedWatch.

The Revatio case illustrates how post‑marketing surveillance can reshape drug labeling and influence market dynamics. Pfizer, the manufacturer, is now required to evaluate long‑term mortality risks in adult PAH patients, a move that may affect prescribing habits across the broader pulmonary hypertension market. Regulators worldwide are likely to monitor similar pediatric data closely, potentially prompting earlier label revisions for other off‑label uses. For investors and industry analysts, the episode highlights the financial and reputational stakes tied to pediatric safety signals in the pharmaceutical sector.